Lurasidone in the treatment of schizophrenia: a critical evaluation

Bruijnzeel, Dawn; Yazdanpanah, Masoud; Suryadevara, Uma; Tandon, Rajiv

doi:10.1517/14656566.2015.1058780

Cited by 14 publications

(11 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical trials show that antipsychotic medications significantly improve psychotic symptoms for patients with schizophrenia [ 221 , 222 , 223 ]. Atypical antipsychotics may partially normalize ROS metabolism and oxidative stress [ 75 ].…”

Section: Role Of Antipsychoticsmentioning

confidence: 99%

“…Lurasidone is an atypical antipsychotic with high affinity for dopamine D2 receptors, noradrenaline alpha-2C receptors, and serotonin 5-HT2A, 5-HT1A, and 5HT7 receptors [ 222 , 250 , 251 ]. A study of 2373 patients with acute schizophrenia found lurasidone was safe and effective, especially with a daily dose of 80 mg [ 251 ].…”

Section: Role Of Antipsychoticsmentioning

confidence: 99%

See 1 more Smart Citation

Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia

Madireddy

2020

Brain Sciences

View full text Add to dashboard Cite

The biochemical integrity of the brain is paramount to the function of the central nervous system, and oxidative stress is a key contributor to cerebral biochemical impairment. Oxidative stress, which occurs when an imbalance arises between the production of reactive oxygen species (ROS) and the efficacy of the antioxidant defense mechanism, is believed to play a role in the pathophysiology of various brain disorders. One such disorder, schizophrenia, not only causes lifelong disability but also induces severe emotional distress; however, because of its onset in early adolescence or adulthood and its progressive development, consuming natural antioxidant products may help regulate the pathogenesis of schizophrenia. Therefore, elucidating the functions of ROS and dietary antioxidants in the pathogenesis of schizophrenia could help formulate improved therapeutic strategies for its prevention and treatment. This review focuses specifically on the roles of ROS and oxidative damage in the pathophysiology of schizophrenia, as well as the effects of nutrition, antipsychotic use, cognitive therapies, and quality of life on patients with schizophrenia. By improving our understanding of the effects of various nutrients on schizophrenia, it may become possible to develop nutritional strategies and supplements to treat the disorder, alleviate its symptoms, and facilitate long-term recovery.

show abstract

Section: Role Of Antipsychoticsmentioning

confidence: 99%

Section: Role Of Antipsychoticsmentioning

confidence: 99%

Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia

Madireddy

2020

Brain Sciences

View full text Add to dashboard Cite

show abstract

“…Lurasidone’s approval as a treatment for schizophrenia was based on the results of a clinical development programme that included five similarly designed, 6-week-long, fixed-dose, placebo-controlled trials and several long-term, open-label maintenance studies (see Electronic Supplementary Material [ESM] Table S1 for details) [19–27]. Details of these clinical trials have been extensively published and reviewed elsewhere [28, 29]; therefore, only a brief overview of key data is provided here.…”

Section: Clinical Trials Of Lurasidone In Adults With Schizophreniamentioning

confidence: 99%

Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia

et al. 2019

View full text Add to dashboard Cite

IntroductionLurasidone is an atypical antipsychotic that was approved in Europe in 2014 for the treatment of schizophrenia in adults aged ≥ 18 years. Clinical experience with lurasidone in Europe is currently limited, and there is therefore a need to provide practical guidance on using lurasidone for the treatment of adults with schizophrenia.MethodsA panel of European psychiatrists with extensive experience of prescribing lurasidone was convened to provide recommendations on using lurasidone to treat adults with schizophrenia.ResultsExtensive evidence from clinical trials and the panel’s clinical experience suggest that lurasidone is as effective as other atypical agents, with the possible exception of clozapine. Lurasidone is associated with a lower propensity for metabolic side effects (in particular, weight gain) and hyperprolactinaemia than most other atypical antipsychotics and has a relatively benign neurocognitive side effect profile. Patients switching to lurasidone from another antipsychotic may experience weight reduction and/or improvements in the ability to focus/concentrate. Most side effects with lurasidone (such as somnolence) are transitory, easily managed and/or ameliorated by dose adjustment. Akathisia and extrapyramidal symptoms may occur in a minority of patients, but these can be managed effectively with dose adjustment, adjunctive therapy and/or psychosocial intervention.ConclusionsGiven the crucial importance of addressing the physical as well as mental healthcare needs of patients, lurasidone is a rational therapeutic choice for adults with schizophrenia, both in the acute setting and over the long term.FundingSunovion Pharmaceuticals Europe Ltd.Electronic supplementary materialThe online version of this article (10.1007/s40120-019-0138-z) contains supplementary material, which is available to authorized users.

show abstract

“…Lurasidone, a second-generation atypical antipsychotic slowly metabolizing medication, has been proven to be successful in treating both disorders [ 1 , 2 ]. Recent literature demonstrated outstanding safety and favorable metabolic adverse effect profiles, making it a compelling option in treating schizophrenia and bipolar disorder [ 3 ]. Lurasidone treatment is associated with significantly less weight gain when compared to olanzapine and quetiapine [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy

Tarzian¹,

Soudan²,

Alhajji³

et al. 2023

Cureus

View full text Add to dashboard Cite

Lurasidone is an antipsychotic medication that blocks dopamine D2 and serotonin 5-hydroxy-tryptamine (5-HT) 2A receptors and affects other serotoninergic and noradrenergic receptors. It has rapid absorption and linear pharmacokinetics. The rates of metabolic syndrome for patients taking lurasidone are comparable to placebo groups. Lurasidone is a safe and effective treatment for patients with acute schizophrenia and bipolar depression. It has been found to improve the brief psychiatric rating scale and other secondary measures in schizophrenic patients and reduce depressive symptoms in bipolar I depression. The once-daily administration of lurasidone is generally well-tolerated and does not cause clinically significant differences in extrapyramidal symptoms, adverse effects, or weight gain compared to a placebo. However, lurasidone's effectiveness in combination with lithium or valproate has been mixed. Further research is needed to determine optimal dosing, treatment duration, and combination with other mood stabilizers. Long-term safety and effectiveness and its use in different subpopulations should also be evaluated.

show abstract

Lurasidone in the treatment of schizophrenia: a critical evaluation

Cited by 14 publications

References 48 publications

Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia

Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia

Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia

Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy

Contact Info

Product

Resources

About